New hope for rare chest cancer patients after other treatments fail
NCT ID NCT06248515
Summary
This study is testing whether a drug called sacituzumab govitecan can help control advanced thymoma and thymic carcinoma in adults whose cancer has continued to grow despite previous treatments. Participants will receive the drug through an IV every three weeks until their cancer worsens or side effects become too severe. Researchers will monitor how many patients' tumors shrink and how long the treatment keeps the cancer from progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lombardi Comprehensive Cancer Center, Georgetown University
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford Cancer Institute
RECRUITINGPalo Alto, California, 94304, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.